The Cemipai is a unique and multi-functional platform dedicated to the study of human pathogens (viruses, bacteria) and drug design. Our service is highly flexible and allows external users to choose from several research, screening and profiling services, in collaboration or agreement services. The Cemipai offers its expertise and know-how at various levels to develop your projects from basic ex vivo research to pre-clinical tests in vivo.
HOSTING YOUR RESEARCH
The CEMIPAI welcomes researchers looking for a BSL3 environnement fully equipped with cutting edge technology. The 360m2 BSL3 facilities can be rented from a week to years. In addition, either only one of the 16 Biological Safety Cabinets can be rented, or a full box containing 3 Biological Safety Cabinets and the required equipment.
Researchers are welcome with their pathogens (and hosts) to conduct their experiments in the best conditions, with the help of experts if needed.
Our platform is open to collaboration with academics and pharmaceutical industries on specific projects for which its high level equipment and expertise will help. In particular, partnering in European or French grant consortiums are welcome.
Do not hesitate to contact us
SCREENING AND PROFILING SERVICES
The CEMIPAI facility is equipped with a set of robotic technologies for automated screening assays.
The platform offers several models of pathogens/hosts for in vitro studies. We partner with BSL3 animal facilities of Montpellier University and with Azelead, a biotech expert in working with Zebrafish. These combinations present a full R&D pre-clinical value chain that starts from drug libraries and ends downstream of human clinical phases.
We have access to the large collection of small molecules from the CNRS chimiotec. We are also in connection with the chemistry institute PĂ´le Balard in Montpellier, expert in the design, synthesis and pharmacology of biomolecules for the treatment of human and animal pathologies.
Any other compound libraries can be tested.
Chargement en cours ...